Technology
Health
Medical

Cesca Therapeutics

$0.31
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell KOOL and other stocks, options, ETFs, and crypto commission-free!

About

Cesca Therapeutics, Inc. engages in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. It operates through the Clinical Development Division and Device Division business segments. Read More The Clinical Development Division segment involves in developing autologous stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology, and orthopedic markets. The Device Division segment includes development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The company was founded by Philip H. Coelho in 1986 and is headquartered in Rancho Cordova, CA.

Employees
86
Headquarters
Rancho Cordova, California
Founded
1986
Market Cap
6.71M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
451.40K
High Today
$0.3291
Low Today
$0.30
Open Price
$0.3291
Volume
86.41K
52 Week High
$2.77
52 Week Low
$0.21

Collections

Technology
Health
Medical
Therapy
US
North America

News

PR NewswireMar 20

Cesca Therapeutics To Announce Financial Results For The Fourth Quarter Ended December 31, 2018 and Host Conference Call On March 25

RANCHO CORDOVA, Calif., March 20, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cellular processing and autologous cell therapies for regenerative medicine, today announced that the Company will release its financial results for the fourth quarter ended December 31, 2018 on Monday, March 25, 2019 after close of trading. A conference call and webcast will follow at 1:30 p.m. PDT/ 4:30 p.m. EDT. To participate in the conference call, please dial 1-844-889-4331 (dom...

71
Guru FocusFeb 25

ThermoGenesis Receives Health Canada Approval of its PXP System for Automated Processing of Bone Marrow Cells

RANCHO CORDOVA, Calif., Feb. 25, 2019 /PRNewswire/ -- ThermoGenesis Corp, a private corporation owned by Cesca Therapeutics (Nasdaq: KOOL), and a market leader in automated cellular processing and autologous cell therapies for regenerative medicine, today announced that it received Health Canada approval of its PXP® System for point-of-care harvesting of purified mononuclear cells and platelets from blood or bone marrow. The ThermoGenesis PXP System is a semi-automated, functionally-closed system that harv...

407

Earnings

-$0.27
-$0.17
-$0.06
$0.04
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.07 per share
Actual
Available Mar 25, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.